Dyer Timothy Mark recorded the disposition and award of 16,413,787 Addex Therapeutics shares on 2026-09-02, with ownership reported at 16,848,979 shares after the award. Investors can distinguish the separate post-transaction share balances and track the accompanying derivative-security entries, including 3,369,796 securities awarded on the same date.

Key Highlights

  • Dyer Timothy Mark’s derivative-security records show 0 after the disposition and 3,369,796 after the award.
  • Dyer Timothy Mark is identified as Addex Therapeutics Ltd.’s chief executive officer.
  • The share entries carry transaction codes D for the disposition and A for the award.

Dyer Timothy Mark recorded the disposition and award of 16,413,787 Addex Therapeutics Ltd. shares on 2 September 2026.

Addex Share and Derivative Entries

The share disposition carries transaction code D, while the award is marked with code A. Both entries use the same date and share quantity. Separate records cover 3,369,796 derivative securities, with the disposition also marked D and the award marked A. Following the derivative-security disposition, Dyer Timothy Mark’s reported holding was 0; after the award, it was 3,369,796 derivative securities. Dyer Timothy Mark’s reported position therefore changes according to the transaction entry being viewed, with separate balances attached to the disposition and award records.

Transaction-Specific Ownership Balances

The share records show one balance after the disposition and another after the award, while the derivative-security records follow the same transaction-specific structure.